See HLS Therapeutics Inc. (74D.F) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.
Earnings call HLS Therapeutics delivered FY2025 revenue of $55.5M (down 2% YoY) and Adjusted EBITDA of $19.6M (up 18% YoY), with strong cash flow and a 23% YoY reduction in net debt. 2026 guidance ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results